Marlodon (Methadone Hydrochloride)

Methadone acts as a full agonist at mu‑opioid receptors in the central nervous system. By binding these receptors, it produces analgesia and suppresses the neurochemical changes that cause opioid withdrawal, offering a steady level of opioid activity that eases cravings and pain.

The appropriate dose of Marlodon is individualized by the prescribing clinician based on the patient’s clinical condition, prior opioid exposure, and response to therapy. Dosage adjustments are made during treatment to achieve optimal control of withdrawal symptoms or pain.

Marlodon is classified as Pregnancy Category C, indicating that risk cannot be ruled out. Use during pregnancy should only occur if the potential benefit justifies the potential risk to the fetus. Methadone is excreted in breast milk; breastfeeding decisions should be made with a healthcare professional.

To request Marlodon, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with shorter‑acting opioids such as morphine, methadone has a longer half‑life, allowing once‑daily dosing for maintenance therapy. Its oral bioavailability and stable plasma concentrations make it suitable for both dependence treatment and chronic pain, though careful cardiac monitoring is required due to QT‑prolongation risk.

Marlodon should be stored at temperatures below 25 °C in its original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and do not use if the packaging is damaged or the tablet appears discolored.

Marlodon is administered orally, typically as a tablet or oral solution, according to the prescriber’s instructions. The dose may be taken with or without food, but consistency in relation to meals helps maintain stable drug levels.

The most serious risks include respiratory depression, which can be fatal if not promptly managed, and cardiac arrhythmias due to QT interval prolongation. Patients should be monitored closely for signs of severe sedation, breathing difficulties, or irregular heart rhythms, especially during dose initiation or changes.

Marlodon is contraindicated in individuals with known hypersensitivity to methadone, those with severe respiratory insufficiency, uncontrolled cardiac arrhythmias, or acute asthma attacks. It should also be avoided in patients taking monoamine oxidase inhibitors within 14 days of starting therapy.